However, IDH2 R140 mutations frequently cooccur with NPM1 mutations, which is associated with a favorable prognosis in newly diagnosed AML but a poor prognosis in relapsed/refractory AML [89,90]. This evidence concerns the gene IDH2 and acute myeloid leukemia.